Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

Drug Safety

Volumn 38, Issue 5, 2015, Pages 455-479

  Baldo, Brian A ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HYBRID PROTEIN;

ANIMAL; CHEMISTRY; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG STABILITY; HUMAN; PROTEIN STABILITY; RISK;

ANIMALS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG STABILITY; GLYCOPROTEINS; HUMANS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; RISK;

EID: 84937763904     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0285-9     Document Type: Review

References (216)

1. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.
2. Huang C, Swanson RV. Peptide-Fc fusion therapeutics: applications and challenges. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals. Applications and challenges. Hoboken: Wiley; 2013. p. 123–42.
3. New molecular entity and new therapeutic biological product approvals for 2014. Available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm429247.htm. Accessed 5 Mar 2015.
4. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. mAbs. 2011;3:415–6.
5. Forbes. Pharma & Healthcare. 1/28/2013. The best selling drugs of all time; Humira joins the elite. Available at http://www.forbes.com/sites/simonking/2013/01/28/the-best-selling-drugs-of-all-time-humira-joins-the-elite/. Accessed 19 July 2014.
6. FDA. CDER therapeutic biologic products. CDER billable biologic product list. Available at http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm. Accessed 19 July 2014.
7. Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2013. doi:10.3109/07388551.2013.834293.
8. Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37:921–43.
9. Chamow SM, Ryll T, Lowman HB, Farson D, editors. Therapeutic Fc-fusion proteins. Weinheim: Wiley-Blackwell; 2014.
10. Schmidt SR. Fusion proteins: applications and challenges. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals. Applications and challenges. Hoboken: Wiley; 2013. p. 3–24.
11. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future prospects. EMBO Mol Med. 2012;4:1015–28.
12. Butler M. Post-translational modification of recombinant proteins. In: Castilho L, Moraes A, Augusto E, Butler M, editors. Animal cell technology: from biopharmaceuticals to gene therapy. New York: Taylor and Francis; 2008. p. 129–46.
13. Rajpal A, Strop P, Yeung YA, et al. Introduction: Antibody structure and function. In: Chamow SM, Ryll T, Lowman HB, Farson D, editors. Therapeutic Fc-fusion proteins. Weinheim: Wiley-Blackwell; 2014. p. 1–44.
14. Beck A, Wagner-Rousset E, Bussat M-C, et al. Trends in glycolylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol. 2008;9:482–501.
15. Beck A, Diemer H, Ayoub D, et al. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Anal Chem. 2013;48:81–95.
16. Zhu L, Guo Q, Guo H, et al. Versatile characterization of glycosylation modification in CTLA4-IG fusion proteins by liquid chromatography-mass spectroscopy. Mabs. 2014;6:1474–85.
17. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
18. Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol. 2009;31:223–36.
19. Qiao SW, Kobayashi K, Johansen FE, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci. 2008;105:9337–42.
20. Schmidt SR. Fusion proteins for half-life extension. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals: applications and challenges. Hoboken: Wiley; 2013. p. 93–106.
21. Walker A, Dunlevy G, Topley P. Albumin-binding fusion proteins in the development of novel long-acting therapeutics. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals: applications and challenges. Hoboken: Wiley; 2013. p. 179–90.
22. Keefe D, Heartlein M, Josiah S. Transferrin fusion protein therapeutics: acetylcholine receptor-transferrin fusion protein as a model. In: Schmidt SR, editor. Fusion protein technologies for biopharmaceuticals: applications and challenges. Hoboken: Wiley; 2013. p. 191–200.
23. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–25.
24. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7:1401–13.
25. Burton DR, Woof JM. Human antibody effector function. Adv Immunol. 1992;51:1–84.
26. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673–80.
27. Stapleton NM, Andersen JT, Stemerding AM, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Commun. 2011;2:599. doi:10.1038/ncomms1608.
28. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174:1483–9.
29. Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci. 1994;91:215–9.
30. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29–35.
31. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–51.
32. Bahner JD, Cao LY, Korman NJ. Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol. 2009;2:111–28.
33. Antoniou C, Vergou T, Dessinioti C, et al. Etanercept: effectiveness and safety data of a retrospective study. J Eur Acad Dermatol Venereol. 2011;25:1113–5.
34. Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–8.
35. Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol. 2011;36:1355–62.
36. Ledingham J, Deighton C, behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatol. 2004;44:157–63.
37. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat. 2004;15:280–94.
38. ® (etanacept). FDA: full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5507lbl.pdf. Accessed 19 July 2014.
39. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522–8.
40. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–5.
41. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med. 2002;136:174.
42. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623–6.
43. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653–6.
44. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum. 2002;47:17–21.
45. Derk CT, DeHoratius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis. 2003;62:372.
46. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003;21:526.
47. Elwood RL, Pelszynski MM, Corman LI. Multifocal septic arthritis and osteomyelitis caused by group A streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J. 2003;22:286–8.
48. Renaud C, Ovetchkine P, Bortolozzi P, et al. Fatal group A streptococcus purpura fulminans in a child receiving TNF-alpha blocker. Eur J Pediatr. 2011;170:657–60.
49. Pagliano P, Attanasio V, Fusco U, et al. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis? Ann Rheum Dis. 2004;63:462–3.
50. Kaur PP, Derk CT, Chatterji M, et al. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2004;31:1663–5.
51. Becart S, Segaert S. Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology. 2008;217:260–1.
52. Manzano V, Ruiz P, Torres M, et al. Severe pneumonia by aciclovir-resistant varicella zoster virus during etanercept therapy. Rheumatology. 2010;49:1791–3.
53. Lassoued S, Sire S, Farny M, et al. Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol. 2004;22:267–8.
54. Gonzalez-Vicent M, Diaz MA, Sevilla J, et al. Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Ann Hematol. 2003;82:649–53.
55. Weiner SM, Krenn V, Koelbel C, et al. Echinococcus multilocularis infection and TNF inhibitor treatment in a patient with rheumatoid arthritis. Rheumatol Int. 2011;31:1399–400.
56. Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs. 1999;57:945–66.
57. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137:893–9.
58. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology. 2002;41:116–7.
59. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000;27:2041–4.
60. Roux CH, Brocq O, Albert C, et al. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Jt Bone Spine. 2004;71:444–5.
61. Cunnane G, Warnock M, Fye KH, et al. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:445–9.
62. Brion HP, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999;131:634.
63. Kekow J, Welte T, Kellner U, et al. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum. 2002;46:843–4.
64. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 2001;40:1317–9.
65. Reitblat T, Reitblat O. Appearance of ANCA-associated vasculitis under tumor necrosis factor-alpha inhibitors treatment. Am J Case Rep. 2013;14:80–2.
66. Lecluse LLA, Dowlatshahi EA, Limpens CEJM, et al. Etanercept: an overview of dermatologic adverse events. Arch Dermatol. 2011;147:79–94.
67. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2000;18:533–4.
68. Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J. 2009;102:304–5.
69. Peek R, Scott-Jupp R, Strike H, et al. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006;65:1259.
70. Dereure O, Guillot B, Jorgensen C, et al. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol. 2004;151:506–7.
71. Haibel H, Spiller I, Strasser C, et al. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports. Ann Rheum Dis. 2004;63(Suppl 1):405.
72. Lai-Cheong J, Warren R, Bucknall R, et al. Etanercept-induced dermatitis in a patient with rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2006;20:614–5.
73. Mangge H, Gindl S, Kenzian H, et al. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alfa therapy. J Rheumatol. 2003;30:2506–7.
74. Brigant F, Clavel G, Chatelain D, et al. A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J. 2011;17:11.
75. Bovenschen JH, Kop EN, Van De Kerkhof PCM, et al. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatol Treat. 2006;17:381–3.
76. Soliotis F, Glover M, Jawad ASM. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis. 2002;61:850–1.
77. Bathelier E, Gunera-Saad N, Berard F, et al. Angiokeratoma induced by injection of etanercept for psoriasis. J Am Acad Dermatol. 2008;59:S124–5.
78. Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol. 2009;23:483–4.
79. Chu DH, Van Voorhees AS, Rosenbach M. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol. 2011;147:1228–30.
80. Kavala M, Zindanci I, Türkoglu Z, et al. Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect. Case Rep Dermatol Med. 2013. doi:10.1155/2013/601412. Article ID 601412.
81. Vasconcelos LMF, Teixeira FM, Francelino EV, et al. Acute generalized exanthematous pustulosis in a 51-year-old patient under etanercept treatment for psoriasis. J Pharmacovigilance. 2014;2:120. doi:10.4172/2329-6887.1000120.
82. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53:457–65.
83. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–9.
84. Van der Laken CJ, Lems WF, van Soesbergen RM, et al. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. 2003;48:269–70.
85. Martinez-Taboad VM, Val-Bernal JF, Pesquera LC, et al. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol. 2006;4:322–3.
86. Gomez-Gallego M, Meca-Lallan J, Fernandez Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol. 2008;59:91–3.
87. Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol. 2008;18:399–402.
88. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17:72–4.
89. Kastrup O, Diener HC. TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol. 2008;255:452–3.
90. Kur-Zalewska J, Swarowska-Knap J, Tlustochowicz W. Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. Pol Arch Med Wewn. 2008;118:234–7.
91. Do HH, Mohamed A, Klistorner A, et al. Ophthalmic manifestations of demyelination secondary to etanercept. Clin Exp Ophthalmol. 2008;36:392–4.
92. van Vollenhoven RF. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol. 2004;22(Suppl 35):S122–5.
93. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.
94. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.
95. Symmons DPM, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004;50:1703–6.
96. Stone JH, Holbrook JT, Marriott MA, Wegener’s Granulomatosis Etanercept Trial Research Group, et al. Solid malignancies among patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2006;54:1608–18.
97. Fryrear RS 2nd, Wiggins AK, Sanqueza O, et al. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol. 2004;51:1026.
98. Comte C, Guilhou J-J, Guillot B, et al. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology. 2008;217:284–5.
99. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol. 2008;26:486–502.
100. Kuravilla J, Leitch HA, Vickars LM, et al. Aplastic anemia following administration of a tumor necrosis factor-alfa inhibitor. Eur J Haematol. 2003;71:396–8.
101. Stern A, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252–6.
102. Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res. 2010;62:764–9.
103. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology. 2008;47:376–7.
104. Haroon M, Daly M, Harney S. Re-challenge with etanercept in patients with etanercept-induced neutropenia. Clin Rheumatol. 2012;31:151–5.
105. Azevedo VF, Silva MB, Marinello DK, et al. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. Rev Bas Reumatol. 2012;52:110–2.
106. Pepper AN, Talreja N, Cowan GM, et al. Lymphopenia induced by etanercept. Ann Allergy Asthma Immunol. 2014;112:262–3.
107. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology. 2010;49:2217–9.
108. Hubscher O, Re R, Iotti R. Pulmonary rheumatoid nodules in an etanercept-treated patient. Arthritis Rheum. 2003;48:2077–8.
109. Watson P, Simler N, Screaton N, et al. Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis. Rheumatology. 2008;47:928–9.
110. Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest. 2002;122:1858–60.
111. Vavricka SR, Wettstein T, Speich R, et al. Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax. 2003;58:278–9.
112. Lindsay K, Melsom R, Jacob BK, et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology. 2006;45:1048–9.
113. Tournadre A, Ledoux-Eberst J, Poujol D, et al. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Jt Bone Spine. 2008;75:215–8.
114. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34:1151–4.
115. Sakaida H, Komase Y, Takemura T. Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept. Mod Rheumatol. 2010;20:611–6.
116. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Invest Allergol Clin Immunol. 2008;18:335–42.
117. Allanore Y, Bremont C, Kahan A, et al. Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept. Clin Exp Rheumatol. 2001;19:356–7.
118. Ishikawa Y, Yukawa N, Kawabata D, et al. A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol. 2011;30:429–32.
119. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor a blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145–52.
120. Park SJ, Kim JH, Shin JI. Is there a link between the use of etanercept and Henoch-Schönlein purpura? Comment on: Henoch-Schönlein purpura in a patient with rheumatoid arthritis receiving etanercept (Eur J Dermatol 2010;20:521–2). Eur J Dermatol. 2011;21:147.
121. Lee A, Kasama R, Evangelisto A, et al. Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006;12:249–51.
122. Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a moncentric cohort. Autoimmun Rev. 2014;13:873–9.
123. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–8.
124. Vial T, Descortes J, Screaton G, et al. Drugs acting on the immune system. In: Aronson JK, editor. Side effects of drugs annual 26. Amsterdam: Elsevier; 2003. p. 400.
125. Abourazzak FE, Guggenbuhl P, Perdriger A, et al. Lupus érythémateux cutané induit par étanercept au cours de la polyarthrite rhumatoïde. [In French]. La Rev Med Interne. 2008;29:744–7.
126. Quismorio A, Brahmbhatt B, Houng M, et al. Etanercept allergy and anaphylaxis. J Rheumatol. 2012;39:2225–6.
127. Crayne CB, Gerhold K, Cron RQ. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis. J Clin Rheumatol. 2013;19:129–31.
128. Moore S, Palmer D, Kallarackal G. Beware angioedema with etanercept. Rheumatology. 2008;47:129 (Abstr 445).
129. Sendur OF, Turan Y, Berkit IK, et al. Angio-edema in a patient treated with etanercept for rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104:488–90.
130. Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108:123–31.
131. Benucci M, Manfredi M, Demoly P, et al. Infection site reactions to TNF-α blocking agents with positive skin tests. Allergy. 2008;63:138–9.
132. Gonzalo-Garijo MA, Pérez-Calderón R. Severe generalized exanthema due to etanercept given for severe plaque psoriasis. Ann Allergy Asthma Immunol. 2008;100:621–2.
133. Rajakulendran S, Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology. 2004;43:1588–9.
134. González-López MA, Martinez-Taboada VM, González-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32:672–4.
135. Winfield H, Lain E, Horn T, et al. Eosinophilic cellulitis like reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142:218–20.
136. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci. 1999;96:185–90.
137. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257:792–5.
138. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793–801.
139. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–53.
140. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66–76.
141. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.
142. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547–57.
143. ® (belatacept). FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125288s0000lbl.pdf. Accessed 22 July 2014.
144. Archdeacon P, Dixon C, Bekin O, et al. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12:554–62.
145. Martin ST, Tichy EM, Gabardi S. Belatacept. A novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011;31:394–407.
146. ® initial risk evaluation and mitigation strategy (REMS) approval. 2011. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM261934.pdf. Accessed 22 July 2014.
147. ® (abatacept). FDA: full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125118s0138lbl.pdf. Accessed 22 July 2014.
148. Ursini F, Naty S, Russo E, et al. Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother. 2013;4(Suppl 1):S29–32.
149. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353:1114–23.
150. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Arthritis Rheum. 2005;52:2263–71.
151. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
152. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(Suppl 46):S46–56.
153. Genovese MC, Tena CP, Covarrubias A, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: long term data from the ACQUIRE trial. J Rheumatol. 2014;41:629–39.
154. Kato K, Satoh T, Nishizawa A, et al. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91:362–3.
155. Conde-Montero E, Babiandrés-Rodriguez O, Mendoza-Cembranos MD, et al. Psoriasiform reactions during treatment with abatacept. Indian J Dermatol Venereol Leprol. 2014;80:92–3.
156. Konsta M, Rallis E, Karameris A, et al. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of etanercept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol. 2012;26:257–8.
157. Golmia A, Grinblat B, Finger E, et al. The development of erythema elevatum diutinium in a patient with juvenile idiopathic arthritis under treatment with abatacept. Clin Rheumatol. 2008;27:105–6.
158. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369:2416–23.
159. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.
160. Kapur S, Bonk ME. Rilonacept (Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. PT. 2009;34:138–41.
161. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013;19:19–29.
162. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes. Arthritis Rheum. 2008;58:2443–52.
163. Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34:2091–103.
164. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology. 2013;52:1285–92.
165. Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15(1):R25. doi:10.1186/ar4159.
166. ® (rilonacept). FDA: full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf. Accessed 22 July 2014.
167. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci. 2002;99:11393–8.
168. ® (ziv-aflibercept). FDA: full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf. Accessed 22 July 2014.
169. ® (aflibercept). FDA: full prescribing information. Adverse reactions. Available at http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed 22 July 2014.
170. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;20:207–14.
171. Wang T-F, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol. 2012;6:19–30.
172. Taberno J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320–31.
173. Chen H, Modiano MR, Neal JW, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014;110:602–8.
174. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
175. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202–8.
176. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results of the COPERNICUS study. Ophthalmology. 2014;121:1414–20.
177. Shimamoto G, Gegg C, Boone T, et al. Peptibodies. A flexible alternative format to antibodies. mAbs. 2012;4:586–91.
178. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696–9.
179. ® (romiplostim). FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125268s077lbl.pdf. Accessed 22 July 2014.
180. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193–206.
181. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.
182. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–99.
183. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for human thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118:4338–45.
184. Leung T, Lokan J, Turner P, et al. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia. Pathology. 2011;43:520–2.
185. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
186. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118:28–36.
187. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178:211–22.
188. Chamian F, Lin S-L, Lee E, et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007;5:27. doi:10.1186/1479-5876-5-27.
189. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821–33.
190. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–27.
191. Lowe NJ, Gonzalez J, Bagel J, et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003;42:224–30.
192. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Therapeutics. 2005;27:1912–21.
193. ® (alefacept). FDA: full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf. Accessed 22 July 2014.
194. Schmidt A, Robbins J, Zic J. Transformed mycosis fungoides developing after treatment with alefacept. J Am Acad Dermatol. 2005;53:355–6.
195. 486IL-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem. 1990;265:11885–9.
196. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med. 1988;167:612–22.
197. Robb RJ, Greene WC. Internalization of interleukin 2 is mediated by the β chain of the high-affinity interleukin 2 receptor. J Exp Med. 1987;165:1201–6.
198. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376–88.
199. ® (denileukin-diftitox). Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103767s5094lbl.pdf. Accessed 22 July 2014.
200. Martin A, Gutierrez E, Muglia J, et al. A multicenter dose-escalation trial with denileukin-diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 2001;45:871–81.
201. Polder K, Wang C, Duvic M, et al. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma. 2005;46:1807–11.
202. Baldo BA, Pham NH. Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer; 2013.
203. FDA. Immunogenicity assessment for therapeutic protein products, 2013. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf. Accessed 22 July 2014.
204. Levin D, Golding B, Strome SE, et al. Fc fusiuon as a platform technology: potental for modulating immunogenicity. Trends Biotechnol. 2015;33:27–34.
205. Vultaggio A, Matucci A, Parronchi P, et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical appearance. Int J Immunopathol Pharmacol. 2008;21:367–74.
206. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy. Focus on hypersensitivity responses. OncoImmunology. 2013;2(10):e26333. doi:10.4161/onci.26333.
207. Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin N Am. 2014;34:615–32.
208. Bavbek S, Aydin Ö, Ataman S, et al. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy. 2011;66:1256–7.
209. Salama A, Schütz B, Kiefel V, et al. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol. 1989;72:127–32.
210. Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev. 2013;32:723–61.
211. Bremmer M, Deng A, Gaspari AA. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: part 2. Dermatitis. 2009;20:243–56.
212. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–33.
213. Hall J, Findeisen J. Successful etanercept desensitization in a patient with severe injection site reactions. J Clin Rheumatol. 2013;19:407–8.
214. Morimoto Y, Weber RW, Meehan RT. Successful etanercept desensitization in etanercept-sensitive patients. American College of Rheumatology 2006 Annual Scientific Meeting, Abstract 474. Available at https://acr.confex.com/acr/2006/webprogram/Paper5156.html. Accessed 22 July 2014.
215. Fellner MJ, Yohe N. Etanercept urticaria in a patient with psoriasis desensitized using a new method. J Drugs Dermatol. 2013;12:1168–9.
216. Bavbek S, Ataman S, Akinci A, et al. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract. 2015. doi:10.1016/j.jaip.2015.01.009.